Navesta opens LKR1.4bn sterile drug plant in Sri Lanka

By Gareth Macdonald contact

- Last updated on GMT

iStock/NatanaelGinting
iStock/NatanaelGinting
Navesta Pharmaceuticals had opened a sterile drug manufacturing facility in Horana, Sri Lanka.

The plant – which is compliant with European Union Good Manufacturing Practices (EU-GMP) and Pharmaceutical Inspection Co-Operation Scheme (PIC/S) standards - will make penicillin-based antibiotics for the local market.

According to Navesta the facility will initially manufacture 50 million vials per year. The firm said it plans to increase production capacity three-fold in the next few years.

Company chairman Sanjaya Jayaratne said: “Navesta’s ultimate aim is to provide a reliable, vertically integrated local supply chain which will provide accessibility of high quality pharmaceuticals for our citizens.”

In 2015​, the Sri Lankan Government introduced laws designed to encourage drug production in the country.

Navesta said the regulations had prompted it to invest LKR1.4bn ($9.1m) in construction and development of the facility

Related news

Related products

show more

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers